Evidence map›Paper›PMID 20700488›Full record

ArticlePloS one2010

EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.

Silverio Perrotta, Valeria Cucciolla, Marcella Ferraro, Luisa Ronzoni, Annunziata Tramontano, Francesca Rossi, Anna Chiara Scudieri, Adriana Borriello, Domenico Roberti, Bruno Nobili and 10 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Silverio PerrottaDepartment of Pediatrics, Second University of Naples, Naples, Italy.
Valeria Cucciolla
Marcella Ferraro
Luisa Ronzoni
Annunziata Tramontano
Francesca Rossi
Anna Chiara Scudieri
Adriana Borriello
Domenico Roberti
Bruno Nobili
Maria Domenica Cappellini
Adriana Oliva
Giovanni Amendola
Anna Rita Migliaccio
Patrizia Mancuso
Ines Martin-Padura
Francesco Bertolini
Donghoon Yoon
Josef T Prchal
Fulvio Della Ragione
University of Campania "Luigi Vanvitelli" · ITEuropean Institute of Oncology · ITOspedale Maggiore · ITUniversity of Utah · USIcahn School of Medicine at Mount Sinai · USUniversity of Naples Federico II · IT

Funding

Tissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0M
NCI NIH HHS P01 CA108671
6 · The paper itself

Abstract

backgroundGain-of-function of erythropoietin receptor (EPOR) mutations represent the major cause of primary hereditary polycythemia. EPOR is also found in non-erythroid tissues, although its physiological role is still undefined. METHODOLOGY/PRINCIPAL

findingsWe describe a family with polycythemia due to a heterozygous mutation of the EPOR gene that causes a G-->T change at nucleotide 1251 of exon 8. The novel EPOR G1251T mutation results in the replacement of a glutamate residue by a stop codon at amino acid 393. Differently from polycythemia vera, EPOR G1251T CD34(+) cells proliferate and differentiate towards the erythroid phenotype in the presence of minimal amounts of EPO. Moreover, the affected individuals show a 20-fold increase of circulating endothelial precursors. The analysis of erythroid precursor membranes demonstrates a heretofore undescribed accumulation of the truncated EPOR, probably due to the absence of residues involved in the EPO-dependent receptor internalization and degradation. Mutated receptor expression in EPOR-negative cells results in EPOR and Stat5 phosphorylation. Moreover, patient erythroid precursors present an increased activation of EPOR and its effectors, including Stat5 and Erk1/2 pathway. CONCLUSIONS/SIGNIFICANCE: Our data provide an unanticipated mechanism for autosomal dominant inherited polycythemia due to a heterozygous EPOR mutation and suggest a regulatory role of EPO/EPOR pathway in human circulating endothelial precursors homeostasis.

Indexed as

Cell DifferentiationAdolescentAdultAntigens, CD34Base SequenceCase-Control StudiesCell MembraneCell ProliferationChild, PreschoolCytoplasmEndothelial CellsErythroid Precursor CellsFemaleHumansK562 CellsMaleAntigens, CD34Receptors, ErythropoietinSTAT5 Transcription Factor

Identifiers

PMID20700488
PMCPMC2916842
OpenAlexW2138988243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.